Prognostic Value of the Expression of p53 in Patients with Non-small Cell Lung Cancer
作者： Biljana Ilievska Poposka , Snezhana Smickova , Simonida Jovanovska Crvenkovska , Beti Zafirovska Ivanovska , Tome Stefanovski
DOI: 10.3889/MJMS.1857-5773.2009.0074
关键词:
摘要: Background. The p53 gene is frequently mutated in non-small-cell lung cancer (NSCLC). However, the effect of mutations on patient prognosis remains unclear. Aim. aim this study to determine association abnormalities with clinical data and patients NSCLC. Material Methods. Tumor tissues from 80 NSCLC were assessed by immunohistochemistry for expression p53. immunohistochemical was performed formalin-fixed, paraffin-embedded sections using LCAB immunoperoxidase method mouse anti-p53 monoclonal antibody (clone DO-7; DAKO). Results. Forty-three (53,75%) revealed aberrant immunostaining Except histological type tumors, there no correlation clinicopathologic features. Kaplan-Meier survival analysis demonstrated that positive status had poor rate (p=0,005 Log Rank test= 7,914). In Cox, regression performance emerged as independent prognostic factors (p<0,009 p<0,000 respectively). Conclusion. results indicated significant predictable factor
cabdirect.org
sci-hub.st 参考文章(32)
J. B. Sørensen, K. Østerlind, Prognostic Factors: From Clinical Parameters to New Biological Markers Springer, Berlin, Heidelberg. pp. 1- 21 ,(1999) , 10.1007/978-3-642-59824-1_1
T Mitsudomi, S Piantadosi, M M Nau, D T Curiel, I Chiba, D L Buchhagen, H Koga, T Takahashi, D D'Amico, D Carbone, Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group. Oncogene. ,vol. 5, pp. 1603- 1610 ,(1990)
Progress and perspective in the treatment of lung cancer Springer Berlin Heidelberg. ,(1999) , 10.1007/978-3-642-59824-1
Steinberg Sm, Mulshine Jl, Linnoila Ri, Ebina M, Relationship of p53 Overexpression and Up-Regulation of Proliferating Cell Nuclear Antigen with the Clinical Course of Non-Small Cell Lung Cancer Cancer Research. ,vol. 54, pp. 2496- 2503 ,(1994)
Steven A. Rosenberg, Vincent T. DeVita, Samuel Hellman, Cancer : Principles and Practice of Oncology ,(1982)
Joëlle Siat, Christian Bronner, Nadine Martinet, Jacques Borrelly, Philippe Scheid, Karim Nabil, Pascal Wild, Béatrice Marie, Jean-Michel Vignaud, Yves Martinet, Gérard Pottier, Taoufik Labib, Richard Sesboüé, Guillaume Farré, Judith Moldvay, Predictive survival markers in patients with surgically resected non-small cell lung carcinoma. Clinical Cancer Research. ,vol. 6, pp. 1125- 1134 ,(2000)
J S Lee, A Yoon, S K Kalapurakal, J Y Ro, J J Lee, N Tu, W N Hittelman, W K Hong, Expression of p53 oncoprotein in non-small-cell lung cancer: a favorable prognostic factor. Journal of Clinical Oncology. ,vol. 13, pp. 1893- 1903 ,(1995) , 10.1200/JCO.1995.13.8.1893
Joan H. Schiller, Sudeshna Adak, Richard H. Feins, Steven M. Keller, Willard A. Fry, Robert B. Livingston, M. Elizabeth M. Hammond, Barbara Wolf, Linda Sabatini, James Jett, Leslie Kohman, David H. Johnson, Lack of Prognostic Significance of p53 and K-ras Mutations in Primary Resected Non–Small-Cell Lung Cancer on E4592: A Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy Journal of Clinical Oncology. ,vol. 19, pp. 448- 457 ,(2001) , 10.1200/JCO.2001.19.2.448
Shimokata K, Kuroishi T, Niimi T, Horio Y, Suyama M, Yamakawa K, Nakamura Y, Ueda R, Hibi K, Takahashi T, Prognostic Significance of p53 Mutations and 3p Deletions in Primary Resected Non-Small Cell Lung Cancer Cancer Research. ,vol. 53, pp. 1- 4 ,(1993)
Helen Han, Rodney J. Landreneau, Tibetha S. Santucci, Ming Y. Tung, Robin S. Macherey, Stanley E. Shackney, Charles D. Sturgis, Stephen S. Raab, Jan F. Silverman, Prognostic value of immunohistochemical expressions of p53, HER-2/neu, and bcl-2 in stage I non–small-cell lung cancer Human Pathology. ,vol. 33, pp. 105- 110 ,(2002) , 10.1053/HUPA.2002.30183